Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.46 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18299189 | 0.80 | TRPA1 (0.56) | METAP2S1PR1TRPA1CYP1A2RXRA | |
| SCHEMBL13961150 | 0.80 | METAP2 (0.47) | METAP2NOS1S1PR1TRPA1CYP1A2 | |
| SCHEMBL28954103 | 0.79 | METAP2 (0.46) | METAP2S1PR1TRPA1CYP1A2RXRA | |
| SCHEMBL2425031 | 0.77 | NOS1 (0.52) | METAP2NOS1TRPA1CSNK2A1DYRK1A | |
| SCHEMBL11577531 | 0.75 | NOS1 (0.53) | METAP2NOS1CSNK2A1DYRK1ATDO2 | |
| SCHEMBL2426106 | 0.75 | METAP2 (0.42) | METAP2S1PR1TRPA1CYP1A2RXRA | |
| SCHEMBL28811084 | 0.75 | METAP2 (0.42) | METAP2S1PR1TRPA1CYP1A2RXRA | |
| SCHEMBL31404481 | 0.73 | RXRA (0.43) | METAP2S1PR1RXRARXRBRXRG | |
| SCHEMBL30726242 | 0.73 | EGLN1 (0.35) | RIPK1EGLN1 | |
| SCHEMBL27033392 | 0.73 | EGLN1 (0.35) | RIPK1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4650345-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF IN MEDICINE | Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025045837-A1 | PESTICIDALLY ACTIVE INDAZOLE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024149242-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2009009411-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | METAP2 4656/4885NOS1 4422/4885S1PR1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.